Product Overview - Cabergoline is a synthetic long-acting oxytocin analog approved for market in February 2016, aimed at preventing postpartum hemorrhage and enhancing uterine contractions [2] - The product's launch enriches the company's core product line and is expected to significantly boost company performance [2] Sales Performance - Terlipressin, a synthetic vasopressin analog, generated sales revenue of ¥68,370,177.72 in the first half of 2016, marking a 35.08% increase compared to the same period last year [3] - The company aims for a 50% revenue growth for Terlipressin by the end of the year through enhanced academic promotion and sales efforts [3] International Market Strategy - The company has a strong R&D capability in peptide drugs and aims to expand its international market presence, including in developed regions like the US, Europe, Japan, and South Korea, as well as emerging markets like India [3] - Plans include increasing overseas registration and market expansion efforts for peptide drugs and raw materials [3] Competitive Advantages - The company has invested 10 years in the R&D of Glatiramer and 7 years in Liraglutide, establishing a competitive edge in the international raw material drug market [4] - The company is recognized as a preferred supplier for major pharmaceutical companies, enhancing its market share and brand recognition [4] Recent Acquisitions and Growth - Following the acquisition of Chengji Pharmaceutical, the company has integrated its management and production systems, leading to significant revenue growth in combination packaging products (¥39,859,100, up 320.49%) and medical devices (¥53,301,000, up 259.29%) in the first half of 2016 [4] - Future plans include leveraging Chengji's production scale and cost advantages to expand sales and improve overall profitability [4]

Group 1: Product Overview - Carboprost is a synthetic long-acting oxytocin analog used to enhance uterine contractions during cesarean sections, preventing uterine atony and postpartum hemorrhage [2] - In China, approximately 16.5 million newborns are born annually, with an expected increase of 2.5 million newborns per year after the full implementation of the two-child policy [2] - The cesarean section rate is around 45%, indicating a market potential of 2-4 billion RMB for Carboprost, as each cesarean section patient may require 1-2 doses [2] Group 2: Market Impact - The approval of Carboprost and its injection formulation by the National Medical Products Administration in February 2016 has diversified the company's core product offerings [2] - The introduction of Carboprost is expected to significantly enhance the company's performance and optimize its product structure [2] Group 3: Collaboration and Development - The non-invasive continuous glucose monitoring wristband project, in collaboration with Pudi Medical, utilizes near-infrared and bio-resistance signals to provide real-time glucose data, improving the quality of life for diabetes patients [3] - Clinical trials for the glucose monitoring wristband are actively progressing in Europe, with ongoing optimizations based on trial feedback [3] Group 4: Production Expansion - The biopharmaceutical production base in Wuhan has commenced construction, covering an area of 342 acres with a planned building area of 250,000 square meters [3] - The project includes a peptide raw material production base, a high-end solid preparation production base, a national-level biopharmaceutical R&D production base, and an administrative service center [3]

Company Overview - Shenzhen Hanyu Pharmaceutical Co., Ltd. was established in 2003, focusing on the research, production, and sales of peptide drugs, recognized as a national high-tech enterprise [2] - The company has established multiple subsidiaries and research centers, including a national peptide drug public laboratory and a production base for peptide drugs [2] Financial Performance - In the first three quarters of 2016, the raw material drug business achieved revenue of approximately CNY 110 million, a year-on-year increase of over 500% [3] - The peptide business generated nearly CNY 90 million in revenue, with a growth rate of about 8% [3] - The revenue from Terlipressin reached CNY 119,401,132.91, reflecting a year-on-year growth of 38.61% [4] Research and Development - Over 30% of the company's employees are involved in R&D, with R&D investment consistently exceeding 10% of sales revenue [3] - The company has applied for over 300 invention patents and has received nearly 200 authorized patents [3] - Hanyu Pharmaceutical has participated in several national-level major scientific projects and has been recognized with various awards for innovation and quality [3] Market Strategy - The company has secured exclusive agency rights for the non-invasive continuous glucose monitoring device GlucoPred in the Chinese market [2] - A strategic partnership with Tencent was established to enhance the management of chronic diseases through mobile internet technology [3] - The company aims to expand its international market presence, particularly in the raw material drug sector, leveraging its R&D and technical advantages [4]

Group 1: Product Overview - Terlipressin is a synthetic vasopressin analog initially developed in the early 1980s, primarily used for treating variceal bleeding due to liver cirrhosis [2] - It is widely applied in clinical settings for conditions such as hepatorenal syndrome, ascites due to cirrhosis, septic shock, burns, acute liver failure, and cardiac arrest [2] - Terlipressin is the only known drug that can improve survival rates in patients with liver cirrhosis-related complications, making it significant in treatment guidelines [2] Group 2: Market Position and Competition - The domestic market for injectable terlipressin is currently dominated by two companies: the original manufacturer, Ferring, and Hanyu Pharmaceutical [3] - Prior to 2009, the terlipressin market in China was monopolized by imported drugs until Hanyu launched its generic version, breaking the monopoly and filling a market gap [3] - Hanyu's terlipressin has shown rapid growth in sales, achieving a leading position in the domestic market [3] Group 3: Marketing Strategies - The marketing strategy for terlipressin combines academic promotion with expert education, focusing on various academic activities to enhance physician awareness [3] - The drug has gained recognition among experts, doctors, and patients due to its clinical efficacy and extensive market cultivation [3] - After being included in the national medical insurance directory, Hanyu plans to intensify academic and sales promotions to solidify and expand its competitive advantage in the market [3]

Group 1: Employee Stock Ownership Plan - The third employee stock ownership plan was terminated due to significant changes in regulatory policies and market conditions, despite attempts to adjust it according to new regulations [2] - The company plans to consider launching a new employee stock ownership plan or other equity incentive methods in the future when conditions are favorable [2] Group 2: Impact of Liraglutide Generic Drug - The global market sales for Liraglutide reached $2.7 billion in 2015 and are expected to grow to $3 billion this year, indicating a positive market outlook [3] - The company is actively pursuing ANDA applications for Liraglutide, which is expected to increase demand and enhance its competitive advantage as a preferred supplier of raw materials [3] Group 3: Future Growth Points - The company anticipates growth in the international market, particularly for Liraglutide and Glatiramer, with ongoing international registration efforts [3] - The company is also targeting both regulated and unregulated markets to expand its market share [3] Group 4: National Medical Insurance Inclusion - The company’s products, Terlipressin and Eptifibatide, are considered popular candidates for inclusion in the national medical insurance directory [4] - The relationship between drug inclusion in insurance and price reduction is not direct and depends on market competition [4] Group 5: Market Outlook for Older Products - The sales of older products like Thymopentin are affected by national policies, but they still maintain a strong market presence due to their widespread clinical applications [4] - The company aims to sustain the market scale of older products while seeking continuous growth in its main business [4]

Group 1: Financial Performance - The total revenue for the first three quarters of 2016 was ¥614,777,608.35, representing a year-on-year growth of 34.37% [2] - The net profit attributable to shareholders for the same period was ¥230,112,682.27, with a year-on-year increase of 32.06% [2] - The overseas market showed significant growth, particularly in the sales of raw materials such as Acetate Glatiramer and Liraglutide [2] Group 2: Market Challenges and Strategies - The company faces challenges in the domestic formulation market due to frequent national policy changes and intense market competition [3] - To address these challenges, the company is adjusting its marketing strategies and focusing on the promotion of new products [3] - Future efforts will include optimizing product structure and increasing the promotion of key products like Terlipressin and Somatostatin [3] Group 3: Research and Development - The total R&D investment for the first three quarters of 2016 was ¥40,246,639.94, accounting for 6.55% of total revenue [3] - The company emphasizes independent innovation and has been enhancing its R&D capabilities by introducing advanced equipment and building a strong R&D team [3] - Ongoing research focuses on chronic disease medications, ensuring compliance with regulations to improve patient quality of life and medication safety [3]

Revenue and Profitability - Revenue for Q3 2022 reached ¥174,434,483.66, an increase of 23.23% compared to the same period last year[7] - Net profit attributable to shareholders was -¥48,558,678.78, a decrease of 46.91% year-on-year[7] - Net profit excluding non-recurring gains and losses was -¥76,185,909.91, an increase of 16.37% compared to the previous year[7] - Total operating revenue for the current period reached ¥530,964,140.72, an increase from ¥507,727,212.06 in the previous period, reflecting a growth of approximately 4.9%[45] - The company reported a net loss of ¥943,471,946.57, worsening from a loss of ¥796,690,192.54 in the previous period[43] - The net profit for the current period is -148,227,434.65, compared to -117,633,535.52 in the previous period, indicating a decline of approximately 26%[49] - Operating profit for the current period is -148,712,993.45, compared to -110,557,242.25 in the previous period, reflecting a worsening performance[49] - Total comprehensive income for the current period is -137,350,762.01, compared to -118,786,170.13 in the previous period, showing a decline of about 15%[51] - The basic and diluted earnings per share are both -0.16, compared to -0.13 in the previous period, reflecting a decline in profitability[51] Cash Flow and Liquidity - Cash flow from operating activities showed a net amount of ¥7,976,018.03, down 93.85% year-on-year[7] - The net cash flow from operating activities decreased by 93.85% to ¥7,976,018.03 compared to ¥129,767,232.40 in the same period last year[23] - Cash inflow from operating activities is 581,413,693.87, down from 699,261,065.58 in the previous period, representing a decrease of approximately 17%[53] - The total cash and cash equivalents at the end of the period stood at $49,608,122.89, down from $177,378,071.75, representing a decrease of approximately 72%[56] - The company’s cash and cash equivalents decreased to ¥55,146,336.36 from ¥138,922,817.15 at the beginning of the year[37] - The net increase in cash and cash equivalents was -¥50,899,761.36, a 74.54% improvement from -¥199,938,204.68 in the same period last year[23] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥3,717,233,449.30, a decrease of 4.84% from the end of the previous year[7] - The total assets decreased to ¥3,717,233,449.30 from ¥3,906,390,317.84, a decline of about 4.8%[43] - Total liabilities decreased to ¥2,193,828,725.82 from ¥2,258,418,141.63, reflecting a reduction of approximately 2.9%[43] - Shareholders' equity attributable to the parent company was ¥1,496,548,242.85, down 5.56% from the end of the previous year[7] - The company's equity attributable to shareholders decreased to ¥1,496,548,242.85 from ¥1,584,661,419.91, a decline of about 5.5%[43] - The long-term borrowings decreased to ¥975,905,375.99 from ¥1,072,274,475.14, a reduction of about 9.0%[43] Research and Development - R&D expenses for the first nine months of 2022 were ¥102,432,535.37, an increase of 47.42% year-on-year[20] - Research and development expenses increased significantly to ¥102,432,535.37, up from ¥69,483,063.11, representing a rise of approximately 47.5%[45] Inventory and Goodwill - The company reported a significant increase in inventory by 40.70% to ¥221,101,092.53 due to increased stocking[18] - The company recorded a 1364.36% increase in goodwill to ¥2,798,778.99, resulting from mergers under different control[18] Financing Activities - Total cash inflow from financing activities decreased by 73.19% to ¥366,002,647.16 from ¥1,365,284,136.16 year-on-year[23] - Cash inflow from financing activities was $366,002,647.16, down from $1,365,284,136.16, indicating a significant reduction in financing cash inflows[56] Regulatory and Business Developments - The company received a registration acceptance notice for the raw material drug liraglutide on July 20, 2022, from the National Medical Products Administration[33] - The company’s subsidiary obtained a processing license for industrial hemp in Yunnan, enhancing its domestic business capabilities[36] - The company initiated a Phase I clinical trial for the HY3000 nasal spray after receiving approval from the National Medical Products Administration on August 24, 2022[36] Other Financial Metrics - The company reported interest expenses of 65,588,610.08, an increase from 52,658,555.46 in the previous period, which is a rise of about 24%[49] - The company recorded a foreign exchange gain of 10,876,672.64, compared to a loss of -1,152,634.61 in the previous period, indicating a significant turnaround[51] - The company incurred credit impairment losses of -11,116,340.66, compared to -6,292,879.85 in the previous period, which is an increase of about 77%[49] - Other income for the current period is 17,833,302.73, down from 39,046,919.65 in the previous period, reflecting a decrease of approximately 54%[49] Audit and Reporting - The company did not undergo an audit for the third quarter report, which may affect the reliability of the financial data presented[58] - The report was issued by the board of directors on October 29, 2022, providing timely insights into the company's financial performance[58]

Financial Performance - The company reported a revenue of 1.5 billion RMB for the first half of 2022, representing a year-on-year increase of 20%[1]. - The net profit attributable to shareholders was 300 million RMB, up 15% compared to the same period last year[1]. - The company's revenue for the first half of 2022 was ¥356,529,657.06, a decrease of 2.63% compared to ¥366,176,108.16 in the same period last year[26]. - The net loss attributable to shareholders was ¥98,223,075.25, representing a significant increase of 269.06% from a loss of ¥26,614,230.70 in the previous year[26]. - The net cash flow from operating activities decreased by 66.65% to ¥31,170,243.64, down from ¥93,458,375.77 in the same period last year[26]. - The basic and diluted earnings per share were both -¥0.11, a decline of 266.67% compared to -¥0.03 in the previous year[26]. - The company reported a significant increase in foreign revenue, which rose by 258.90% to ¥40.84 million, while domestic revenue decreased by 11.02% to ¥315.69 million[66]. - The company reported a net loss of approximately ¥99.34 million, compared to a net loss of ¥25.64 million in the same period last year, indicating a deterioration in profitability[200]. Research and Development - The company plans to invest 200 million RMB in R&D for new drug development in the next fiscal year[1]. - The company is developing a new COVID-19 peptide nasal spray in collaboration with the Chinese Academy of Microbiology[17]. - The company has partnered with Shenzhen National Infectious Disease Clinical Medical Research Center to develop a home-use COVID-19 antigen testing kit[17]. - The company plans to develop a peptide vaccine based on a technology transfer agreement with the Chinese Center for Disease Control and Prevention[17]. - Research and development expenses increased by 28.13% to ¥74.83 million, primarily due to higher costs associated with innovative drug development[64]. - The company is committed to increasing R&D investment in innovative drugs and has established partnerships with renowned research institutions to enhance its product pipeline[89]. - The company has maintained a high level of R&D investment, focusing on proprietary technologies for peptide drug production, which has led to significant advancements in efficiency and quality[50]. Market Expansion - The company has expanded its market presence in Southeast Asia, achieving a 30% growth in sales in that region[1]. - User data indicates a 25% increase in the number of active patients using the company's products[1]. - The company is actively expanding sales channels and has signed cooperation agreements with well-known distributors to enhance product presence in pharmacies[86]. - The company is collaborating with national research institutions on the HY3000 project to leverage their research capabilities and reduce financial pressure[95]. Product Development - A new product line is set to launch in Q4 2022, expected to contribute an additional 100 million RMB in revenue[1]. - The company has 24 peptide drugs, 9 new drug certificates, and 17 clinical approvals, indicating a strong product pipeline[51]. - The company’s product line includes six major series, including specialty APIs, injectables, and medical devices[34]. - The injection of somatostatin is indicated for acute esophageal variceal bleeding and has been recognized in multiple clinical guidelines[36]. - The injection of carbetocin is designed for postpartum hemorrhage prevention and offers improved safety and efficacy compared to traditional oxytocin[39]. Financial Management - The company has a mature financial management system, ensuring efficient capital allocation and risk control, which supports investment decisions[56]. - The company reported a significant increase in financial expenses, which rose to approximately ¥41.86 million from ¥30.83 million, marking an increase of 35.8% year-over-year[200]. - The company has a strong management team with extensive industry experience, fostering a high-efficiency and service-oriented management environment[55]. Risk Management - Risk factors related to regulatory changes and market competition have been identified, with strategies in place to mitigate these risks[1]. - The company is addressing risks related to drug price reductions by adapting its product line and marketing strategies to maintain sales growth[88]. - The company has implemented measures to prevent core technology leakage, including signing confidentiality agreements with key personnel and enhancing information security systems[90]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, with a total hazardous waste discharge of 244.459 tons in 2021[109]. - The company achieved compliance in various pollutant discharge standards, including COD at 25.60 mg/l against a standard of 345 mg/l, and BOD at 16.75 mg/l against a standard of 150 mg/l[109]. - The company has established a monitoring system for hazardous waste, ensuring that all waste is collected and treated properly[109]. - The company has received no objections or negative feedback regarding the incentive plan from the supervisory board during the public notice period[105]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,729[172]. - The largest shareholder, Zeng Shaogui, holds 16.75% of the shares, amounting to 153,606,167 shares[173]. - The company has a repurchase account holding 33,685,704 shares, representing 3.67% of the total share capital[174]. - The total amount of pledged shares by the largest shareholder, Zeng Shaogui, is 87,150,000 yuan[175]. Corporate Governance - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[80][81]. - The company has not reported any product quality incidents since its establishment, reflecting its strong commitment to quality management[93]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[177].

Financial Performance - The company's revenue for Q1 2022 was ¥167,212,356.18, a decrease of 6.36% compared to ¥178,572,479.97 in the same period last year[5] - The net profit attributable to shareholders was -¥57,654,813.97, representing a decline of 345.70% from ¥23,465,958.26 in Q1 2021[5] - The basic and diluted earnings per share were both -¥0.06, a drop of 300.00% from ¥0.03 in the same quarter last year[5] - Total operating revenue for the first quarter was CNY 167,212,356.18, a decrease of 6.5% from CNY 178,572,479.97 in the previous period[38] - Net profit for the period was a loss of CNY 58,377,053.71, compared to a profit of CNY 23,527,246.35 in the previous year[41] - The total comprehensive income attributable to the parent company was -58,061,508.86 CNY, compared to 24,834,756.08 CNY in the previous period[44] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 70.59%, amounting to ¥20,715,953.56 compared to ¥70,450,145.87 in the previous year[5] - Cash inflow from operating activities was 195,065,288.49 CNY, down from 201,372,687.13 CNY in the previous period[46] - Cash and cash equivalents at the end of the period totaled 108,536,391.98 CNY, compared to 653,813,006.77 CNY at the end of the previous period[53] - The company reported a cash inflow from financing activities of 23,073,485.61 CNY, down from 1,022,260,000.00 CNY in the previous period[53] - The company paid 12,478,692.05 CNY in debt repayments during the period, compared to 747,079,782.98 CNY in the previous period[53] - The company's cash and cash equivalents were not specified, but the overall financial position indicates a tightening of liquidity[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,778,314,755.91, down 3.28% from ¥3,906,390,317.84 at the end of the previous year[5] - Total liabilities decreased to CNY 2,192,395,964.52 from CNY 2,258,418,141.63, a reduction of 2.9%[36] - The company reported a total current assets of CNY 1,021,172,281.04 at the end of the period, down from CNY 1,155,073,227.12 at the beginning of the year, indicating a decrease of approximately 11.6%[30] Investment and Expenses - The company's financial expenses increased by 39.37% to ¥21,251,449.59, primarily due to interest expenses related to the Wuhan biopharmaceutical production base project[13] - Investment income showed a significant loss of -¥2,802,237.72, a decline of 1692.51% compared to a profit of ¥175,963.10 in Q1 2021[13] - Total operating costs amounted to CNY 153,986,253.73, down 4.5% from CNY 161,043,355.50[38] - Research and development expenses were CNY 21,750,925.60, a decrease of 28.8% from CNY 30,561,626.25[41] Shareholder Equity and Stock - The total equity attributable to shareholders decreased by 1.77% to ¥1,556,599,911.05 from ¥1,584,661,419.91 at the end of the previous year[5] - The total number of restricted shares at the beginning of the period was 287,730,918, with 69,214,445 shares released during the period, resulting in an ending balance of 218,516,753 restricted shares[25] - The company approved a stock incentive plan granting 14.4 million restricted shares to 205 incentive targets at a price of CNY 9.63 per share[27] Operational Highlights - The company experienced a 187.87% increase in advance receipts, amounting to ¥7,277,365.76, compared to ¥2,528,024.89 in the same period last year[9] - The company signed a binding letter of intent with Shenzhen National Infectious Disease Clinical Medical Research Center to develop a home-use rapid COVID-19 antigen test kit, with related patents currently under application[26] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[40] - The company is focusing on cost control measures to improve profitability in the upcoming quarters[40] Other Financial Metrics - The company reported a net operating profit of CNY -54,215,401.81, compared to CNY 24,445,611.03 in the previous period[41] - The company’s accounts receivable decreased to CNY 253,467,595.82 from CNY 270,977,112.96, a decline of approximately 6.5%[30] - The company’s other receivables decreased significantly from CNY 51,838,569.92 to CNY 25,936,841.28, a reduction of about 50%[30] - The company’s trading financial assets decreased to CNY 366,160,715.40 from CNY 477,675,715.02, a decline of approximately 23.3%[30] - The company’s long-term equity investments remained stable at CNY 6,008,996.58 compared to CNY 6,010,078.18 at the beginning of the year[30] Audit Status - The report for the first quarter was not audited[54]

Industry Impact and Market Conditions - The company reported a significant impact on the pharmaceutical industry due to ongoing price control policies, leading to substantial price reductions for drugs, which could affect profitability if not managed properly [6]. - The company is adapting to structural adjustments in the pharmaceutical market due to intensified competition and policy changes [88]. - The company recognizes that cost control will be a core competitive advantage for generic drug companies amid ongoing price reductions and procurement policies [168]. Product Development and Innovation - The company is engaged in high-risk, high-investment, and long-cycle product development in the peptide drug sector, with substantial financial commitments required throughout the development and approval process [7]. - The company is currently developing a COVID-19 nasal spray, with preclinical studies completed, but faces uncertainties regarding efficacy and regulatory approval in future clinical trials [12]. - The company plans to launch three new products in 2022, focusing on innovative drug development and targeting unmet medical needs [25]. - The company is focused on expanding its market presence and enhancing competitiveness in the specialty raw materials sector, particularly as regulatory pressures increase [56]. - The company aims to enhance its core competitiveness through a focus on innovative drug development and strategic collaborations [89]. Financial Performance - Shenzhen Hanyu Pharmaceutical Co., Ltd. reported a total revenue of CNY 1.2 billion for the fiscal year 2021, representing a year-on-year growth of 15% [25]. - The company achieved a net profit of CNY 300 million in 2021, an increase of 20% compared to the previous year [25]. - The profit distribution plan for shareholders includes no cash dividends or stock bonuses, with a capital reserve transfer of 0 shares for every 10 shares held [12]. - The gross margin for the year was reported at 60%, indicating strong cost management and pricing strategies [25]. - The company has set a revenue guidance of CNY 1.5 billion for 2022, reflecting a growth target of 25% [25]. Research and Development - Hanyu Pharmaceutical is investing CNY 200 million in R&D for new drug formulations and technologies in the next fiscal year [25]. - The company maintains a high R&D expenditure, focusing on innovative drug development and market expansion strategies [64]. - The company has advanced automated peptide synthesis and purification systems, which support its R&D and production capabilities in the peptide drug sector [47]. - The company emphasizes talent management and development, ensuring a skilled workforce to support its growth initiatives [63]. Regulatory Compliance and Quality Management - The company has established a comprehensive quality management system, achieving certifications from various international standards, but risks related to product quality may arise as production scales up [11]. - The company’s raw materials are certified by multiple international standards, including US cGMP and EU GMP, ensuring high-quality management levels [60]. - The company has successfully passed consistency evaluations for multiple injection products, indicating strong compliance with regulatory standards [99]. Market Strategy and Expansion - The company aims to expand its market presence in Southeast Asia, targeting a 10% market share by 2025 [25]. - The company is actively pursuing partnerships with local distributors to enhance its distribution network and improve market penetration [25]. - The company plans to explore new market opportunities in emerging regions such as Africa and Latin America, leveraging its EU GMP certification and consistency evaluation approvals [168]. Talent Management and Organizational Structure - The company faces a talent shortage in high-end research and development due to its strategic shift towards innovation, which could hinder future growth [10]. - The company has established a performance evaluation and incentive system for senior management, ensuring transparency in evaluation standards and procedures [179]. - The company has a complete governance structure, including a general meeting of shareholders, board of directors, and supervisory board, ensuring compliance with legal regulations [184]. Acquisitions and Investments - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach [25]. - The company acquired a 51% stake in Jiangxi Huihua Pharmaceutical Co., Ltd. for CNY 4.08 million during the reporting period [113]. - The company has invested CNY 50,218.29 in the peptide drug production base construction project, achieving an investment progress of 102.93% [144]. Leadership and Governance - The company has a diverse board with members holding advanced degrees from prestigious institutions, enhancing its governance structure [198]. - The company experienced a change in financial leadership, with the CFO resigning on July 13, 2021, due to personal reasons [194]. - The company reported a significant leadership transition with the appointment of new vice presidents on December 1, 2021 [196].